Pancreatic cancer affects approximately 670 people in Ireland each year, carrying a five-year survival rate of just 13%. According to Professor Giuseppe Kito Fusai, a consultant hepato-pancreato-biliary surgeon, the disease remains difficult to detect early because it typically produces silent, advanced-stage diagnoses.
Vague symptoms often delay pancreatic cancer detection
Most patients present with non-specific early signs that mimic other conditions. Professor Fusai notes that vague abdominal pain, backache, and weight loss frequently delay detection. These overlapping symptoms mean the disease is often found only after it has spread to other organs.
Specific red-flag indicators demand urgent medical evaluation. The development of jaundice—signified by yellow discoloration of the skin and the whites of the eyes alongside dark urine—points to a blocked bile duct caused by a growth from the pancreas. Newly onset diabetes can serve as an early warning sign that requires immediate clinical scans and investigation.
Evaluating Established Risk Factors
A comprehensive scoping review published in BMC Cancer analyzed 130 observational studies and mapped 16 major risk themes across behavioral, metabolic, clinical, genetic, environmental, and social domains. Substance use emerged as the most frequently investigated topic in the literature.
Clinical risk factors identified across medical literature include increasing age and a family history involving a first-degree relative or inherited gene changes such as BRCA2. Professor Fusai emphasizes that smoking remains one of the biggest and most important risk factors of pancreatic cancer. Excessive alcohol consumption can trigger chronic pancreatitis, an inflammatory condition closely linked to elevated cancer risk. Obesity, being overweight, and diabetes round out the primary metabolic risk factors highlighted by researchers.
CT scans identify tumors for potential surgical resection
When clinicians investigate potential malignancies, the gold standard diagnostic tool remains a contrast-enhanced CT scan capable of showing a clear pancreatic mass. Physicians may order supplementary liver MRIs or FDG PET scans, followed by a biopsy if additional confirmation is required.
Treatment pathways depend on tumor size, exact location, general patient health, and whether the cancer has spread. Only about 15% of newly diagnosed patients have operable tumors upon discovery, according to Professor Fusai. For these individuals, surgeons perform radical resections, such as the complex Whipple procedure for tumors located in the head of the pancreas. Patients with inoperable cases may receive chemotherapy or radiotherapy designed to control the cancer and extend survival.
Frequently Asked Questions About Pancreatic Cancer
What percentage of pancreatic cancers are exocrine tumors?
Approximately 95% of all pancreatic cancers are exocrine cancers, with pancreatic ductal adenocarcinoma representing the vast majority of those diagnoses, according to Professor Fusai.
What methodology did the recent BMC Cancer scoping review utilize?
The review examined 130 observational studies published through July 2026, adhering to the Joanna Briggs Institute methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines.
Which diagnostic imaging test serves as the clinical gold standard?
A contrast-enhanced CT scan is considered the gold standard imaging test to reveal a mass within the pancreas.
Related reading